Malignant ascites in ovarian cancer: cellular, acellular, and biophysical determinants of molecular characteristics and therapy response

BP Rickard, C Conrad, AJ Sorrin, MK Ruhi, JC Reader… - Cancers, 2021 - mdpi.com
Simple Summary Accumulation of excess fluid in the abdomen typically indicates abnormal
function or disease, such as cancer, in the underlying tissues. This accumulation of fluid, or …

Metabolic plasticity in chemotherapy resistance

MA Desbats, I Giacomini, T Prayer-Galetti… - Frontiers in …, 2020 - frontiersin.org
Resistance of cancer cells to chemotherapy is the first cause of cancer-associated death.
Thus, new strategies to deal with the evasion of drug response and to improve clinical …

The role of sphingosine‐1‐phosphate and ceramide‐1‐phosphate in inflammation and cancer

NC Hait, A Maiti - Mediators of inflammation, 2017 - Wiley Online Library
Inflammation is part of our body's response to tissue injury and pathogens. It helps to recruit
various immune cells to the site of inflammation and activates the production of mediators to …

Targeting sphingolipids for cancer therapy

O Companioni, C Mir, Y Garcia-Mayea… - Frontiers in …, 2021 - frontiersin.org
Sphingolipids are an extensive class of lipids with different functions in the cell, ranging from
proliferation to cell death. Sphingolipids are modified in multiple cancers and are …

Inhibitors of the sphingomyelin cycle: Sphingomyelin synthases and sphingomyelinases

M Adada, C Luberto, D Canals - Chemistry and physics of lipids, 2016 - Elsevier
Sphingolipids are a class of bioactive lipids, which are key modulators of an increasing
number of physiologic and pathophysiologic processes that include cell cycle, apoptosis …

Evolving concepts in cancer therapy through targeting sphingolipid metabolism

JP Truman, M García-Barros, LM Obeid… - Biochimica et Biophysica …, 2014 - Elsevier
Traditional methods of cancer treatment are limited in their efficacy due to both inherent and
acquired factors. Many different studies have shown that the generation of ceramide in …

[HTML][HTML] Mammalian sphingosine kinase (SphK) isoenzymes and isoform expression: challenges for SphK as an oncotarget

D Hatoum, N Haddadi, Y Lin, NT Nassif… - Oncotarget, 2017 - ncbi.nlm.nih.gov
The various sphingosine kinase (SphK) isoenzymes (isozymes) and isoforms, key players in
normal cellular physiology, are strongly implicated in cancer and other diseases. Mutations …

Recent advances in the development of sphingosine kinase inhibitors

MR Pitman, M Costabile, SM Pitson - Cellular signalling, 2016 - Elsevier
Abstract Sphingosine kinase (SK) 1 and 2 are lipid kinases that catalyse the formation of
sphingosine 1-phosphate (S1P), a potent signalling molecule with a wide array of cellular …

The Sphingosine Kinase 2 Inhibitor ABC294640 Reduces the Growth of Prostate Cancer Cells and Results in Accumulation of Dihydroceramides In Vitro and In Vivo

H Venant, M Rahmaniyan, EE Jones, P Lu… - Molecular cancer …, 2015 - AACR
Despite recent advances in the development of novel therapies against castration-resistant
prostate cancer, the advanced form of the disease remains a major treatment challenge …

Sphingolipid metabolism in the development and progression of cancer: one cancer's help is another's hindrance

A Piazzesi, SY Afsar… - Molecular …, 2021 - Wiley Online Library
Cancer development is a multistep process in which cells must overcome a series of
obstacles before they can become fully developed tumors. First, cells must develop the …